MedTrace Logo

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

NCT02319941 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2017-06-16

No results posted yet for this study

Summary

The purpose of this study is to compare Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients with Acute Coronary Syndromes

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

ticagrelor

DRUG

clopidogrel

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Roche Pharma AG

    collaborator INDUSTRY

  • KBM pharm

    collaborator UNKNOWN

  • Seung-Jung Park

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-20
Primary Completion
2017-02-14
Completion
2017-03-10

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02319941 on ClinicalTrials.gov